Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 16/20 | 0.66 |
| ▸ | MAPT | P10636 | 10/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | RECQL | P46063 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 8/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929976 | 0.94 | ALDH1A1 (0.57) | ALDH1A1MAPTHSD17B10RECQLPOLB | |
| SCHEMBL930889 | 0.79 | ADORA2A (0.55) | ALDH1A1MAPTHSD17B10RECQLPOLB | |
| SCHEMBL930501 | 0.79 | MAPT (0.65) | ALDH1A1MAPTHSD17B10RECQLPOLB | |
| SCHEMBL929756 | 0.78 | ALDH1A1 (0.57) | ALDH1A1MAPTHSD17B10RECQLPOLB | |
| SCHEMBL1718383 | 0.77 | ALDH1A1 (1.00) | ALDH1A1MAPTHSD17B10RECQLPOLB | |
| SCHEMBL4206219 | 0.72 | HSD17B10 (1.00) | ALDH1A1MAPTHSD17B10POLBALOX15 | |
| SCHEMBL929613 | 0.72 | ADORA2A (0.65) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL930406 | 0.72 | ADORA2A (0.63) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4210644 | 0.72 | ALDH1A1 (1.00) | ALDH1A1MAPTHSD17B10RECQLPOLB | |
| SCHEMBL930362 | 0.71 | ADORA2A (0.56) | ALDH1A1HSD17B10RECQLTSHRADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| EP-1722798-B1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | ADORA3, P2RY10, ADORA2A | ALDH1A1 1455/4885MAPT 4220/4885HSD17B10 1799/4885 |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | ALDH1A1 562/4885MAPT 3556/4885HSD17B10 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.